Rheumatoid Arthritis
Conditions
Brief summary
The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).
Interventions
OTHERNon-interventional
Non-interventional
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age at enrollment * Confirmed diagnosed with RA * Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site
Exclusion criteria
* Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels * Was followed at the site for less than 1 year since biologic treatment initiation * Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of patients discontinuing treatment before completing 12 months of therapy | approximately 1 year |
| time from treatment initiation to discontinuation | approximately 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Health Assessment Questionnaire | approximately 1 year | Health Assessment Questionnaire (HAQ) |
| C-reactive Protein Levels | approximately 1 year | C-reactive protein (CRP) levels |
| Distribution of Healthcare Resource Utilization (HCRU) | approximately 1 year | — |
| Joint Erosions | approximately 1 year | Measured by radiographic reports |
| Erythrocyte Sedimentation Rate | approximately 1 year | Erythrocyte sedimentation rate (ESR) levels |
| Disease Activity Score | approximately 1 year | Disease Activity Score (DAS) |
Countries
United States
Outcome results
None listed